Orbimed Capital Gp VII LLC and 2 Others Sells $39M of Enliven Therapeutics Inc (ELVN) — SEC Form 4, Jun 24, 2026

Open-Market Net Sale · SEC Form 4
−$39,014,046

Equity position changed by -79.7%

Reporting Owners
Orbimed Capital Gp VII LLC
10%+
Orbimed Advisors LLC
10%+
Orbimed Genesis Gp LLC
10%+
TXN 2026-06-22 · FILED 2026-06-24
Equity Position 219K sh 1,079,528 → 219,405
Equity Change -79.7% shares held after vs before
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Enliven Therapeutics Inc

ELVN CIK 0001672619
All Enliven Therapeutics Inc insider activity
Filing Date
2026-06-24
Report Date
2026-06-24
Accession No.
0000947871-26-000653
Accepted At
2026-06-24 23:19 UTC
Reporting Owners
Name Relationship
Orbimed Capital Gp VII LLC CIK 0001760648
10% Owner
Orbimed Advisors LLC CIK 0001055951
10% Owner
Orbimed Genesis Gp LLC CIK 0001808744
10% Owner
Orbimed Capital Gp VII LLC at Enliven Therapeutics Inc Full insider history
Bought (12 mo) —
Sold (12 mo) $51,683,034
More from this insider at Enliven Therapeutics Inc
2026-06-17 Sell -$12,668,988 View
2024-05-20 Sell -$22,877,262 View
2023-05-19 Exercise — View
2023-02-27 Award — View
2021-07-16 Buy +$9,999,996 View
All filings by this insider at Enliven Therapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1F3 2026-06-22 S - Sale 24,846 D $45.38 -$1,127,511 220,882 Indirect See Footnotes
Common StockF1F3 2026-06-22 S - Sale 1,477 D $45.00 -$66,465 219,405 Indirect See Footnotes
Common StockF2F3 2026-06-22 S - Sale 787,024 D $45.38 -$35,715,149 6,601,878 Indirect See Footnotes
Common StockF2F3 2026-06-22 S - Sale 46,776 D $45.00 -$2,104,920 6,555,102 Indirect See Footnotes
Footnotes (3)
F1
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis. Show more
F2
These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII. Show more
F3
This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Show more

Related filings at Enliven Therapeutics Inc

Institutional Holders
13F holders · Jun 30, 2026 212 institutional managers reporting a position
Largest by reported value
  1. Fmr Llc $509M
  2. Orbimed Advisors Llc $344M
  3. Polar Capital Holdings Plc $326M
5%+ Holders · 13D/G 6 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Enliven Therapeutics Inc
All Enliven Therapeutics Inc insider activity
GET /v1/forms/4/0000947871-26-000653 API docs
View Original SEC Filing